Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients
Information source: University Hospital, Antwerp
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: COPD
Intervention: Salbutamol (Drug); ipratropium bromide (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: University Hospital, Antwerp Official(s) and/or principal investigator(s): Wilfried A De Backer, MD PhD, Principal Investigator, Affiliation: University Hospital, Antwerp
Summary
The objectives of this study are to assess the effect of salbutamol in comparison with
ipratropium bromide on the geometry of central and peripheral airways and to correlate
spirometric indices with the Computational Fluid Dynamics (CFD) based calculated airway
volumes and resistances for both compounds.
Clinical Details
Official title: Open, Randomized, Two-Way Crossover, Pilot Study to Assess the Effect of Salbutamol in Comparison With Ipratropium Bromide on Central and Peripheral Airway Dimensions in COPD Patients
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The primary objective of this study is to assess the effect of a single dose of salbutamol in comparison with ipratropium bromide on central and peripheral small airways with high-resolution/multislice CT scan imaging technique.
Secondary outcome: The secondary objectives are to evaluate effects on spirometric indices to correlate these with the CFD based calculated airway volumes and resistances for both compounds and to evaluate the safety of the products.
Detailed description:
Salbutamol (VentolinTM) is a short acting beta agonist (SABA) which is used to treat
wheezing, dyspnea and breathing difficulties caused by asthma and COPD. Further, it is also
used to prevent bronchospasm during exercise.
Ipratropium bromide (Atrovent® HFA) is a short acting anticholinergic bronchodilator (short
acting muscarinic antagonist (SAMA)) that improves lung function, dyspnea, exercise
tolerance and health-related quality of life in patients with COPD. Studies have also shown
that ipratropium bromide might reduce COPD exacerbations and related hospitalisations
because the extended bronchodilatation might reduce infection rates by improving clearance
of respiratory secretions.
In this open, randomized, two-way crossover, pilot study the effect of salbutamol in
patients with moderate and severe COPD will be examined in comparison with the effects of
ipratropium bromide. These patients will receive 400 µg salbutamol and 80 µg ipratropium
bromide in a randomized crossover design.
The objectives of this study are to assess the effect of salbutamol in comparison with
ipratropium bromide on the geometry of central and peripheral airways and to correlate
spirometric indices (as Forced Expiratory Volume in one second (FEV1) and Tiffeneau index)
with the Computational Fluid Dynamics (CFD) based calculated airway volumes and resistances
for both compounds.
Eligibility
Minimum age: 40 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Patients with documented COPD based on the following criteria:
- Smoking history of at least 10 pack-years.
- Decreased Tiffeneau index (FEV1/(F)VC < 0. 70).
2. Patients aged ≥ 40 years.
3. Patients should present moderate to severe COPD with an FEV1 between 30 and 80% of
predicted (GOLD 2 and 3).
4. Patients should be treated according to GOLD guidelines.
5. Able to inhale study drug.
6. Maintained on stable respiratory medications for 6 weeks prior to visit 1.
7. Able to perform lung function tests.
8. Able to follow study procedures.
Exclusion Criteria:
1. Patients who are allergic to salbutamol, ipratropium bromide or to another element of
the product.
2. Patients allergic to sojalecithin and products on the basis of soja and peanut.
3. Patients who have or ever had glaucoma.
4. Patients with urinary problems, prostate hyperplasy or bladder-neck obstruction.
Patients whose symptoms are controlled on treatment may be included.
5. Patients with a recent history (i. e. six months or less) of myocardial infarction.
6. Patients with any unstable or life threatening cardiac arrhythmia.
7. Patients with severe kidney insufficiency (creatinine clearance ≤50 ml/min)a.
8. Patients below the age of 40.
9. Patients who are pregnant or are breast-feeding.
10. Patients who are treated with other anticholinergic medications, that cannot be
stopped during the study period.
11. A respiratory infection or exacerbation of COPD in the four weeks prior to screening.
12. Significant alcohol or drug abuse within the past 12 months.
13. Participation in another trial with an investigational drug within one month or six
half lives (whichever is greater) prior to screening visit.
14. Known active tuberculosis.
15. A history of asthma, cystic fibrosis, central bronchiectasis, interstitial lung
disease or pulmonary thromboembolic disease.
16. A history of thoracotomy with pulmonary resection.
17. Active or untreated malignancy.
18. Use of oral corticosteroid medication at unstable doses (i. e. less than six weeks on
a stable dose) or at doses ≥ 10 mg/day.
a Cockroft's formulae should be applied: in male: creatinine clearance = (140-age) x
weight / 72 x creatininemia in female: creatinine clearance = 0. 85 x (140-age) x weight /
72 x creatininemia
Locations and Contacts
Antwerp University Hospital, Antwerp 2650, Belgium
Additional Information
Starting date: June 2008
Last updated: June 1, 2009
|